Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Cash from Operations (2016 - 2025)

Palisade Bio (PALI) has disclosed Cash from Operations for 16 consecutive years, with 3553000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 13.41% to 3553000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 10084000.0, a 19.7% increase, with the full-year FY2024 number at 12193000.0, down 9.52% from a year prior.
  • Cash from Operations was 3553000.0 for Q3 2025 at Palisade Bio, down from 1817000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1250000.0 in Q1 2021 to a low of 3764000.0 in Q1 2022.
  • A 5-year average of 2852437.5 and a median of 3086500.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: plummeted 201.12% in 2022, then skyrocketed 48.07% in 2025.
  • Palisade Bio's Cash from Operations stood at 1250000.0 in 2021, then plummeted by 164.48% to 3306000.0 in 2022, then grew by 16.94% to 2746000.0 in 2023, then increased by 13.29% to 2381000.0 in 2024, then tumbled by 49.22% to 3553000.0 in 2025.
  • Per Business Quant, the three most recent readings for PALI's Cash from Operations are 3553000.0 (Q3 2025), 1817000.0 (Q2 2025), and 2333000.0 (Q1 2025).